Tempus AI Inc. Celebrates a Decade of Discovery with 1,500 Research Projects Advancing Precision Medicine

Reuters

05-28

<a href="https://laohu8.com/S/TEM">Tempus AI</a> Inc. Celebrates a Decade of Discovery with 1,500 Research Projects Advancing Precision Medicine

Tempus AI Inc. has announced its involvement in nearly 1,500 research projects over the past decade, marking a significant milestone in its mission to advance precision medicine and improve patient care. Utilizing its AI-powered platform, Tempus has collaborated with top academic institutions, community health systems, and biopharma organizations to propel cutting-edge research. Notably, Tempus has contributed to approximately 1,000 biopharma research projects and nearly 500 provider-led initiatives. Their diagnostic assays have yielded clinically-relevant insights across more than 200 projects. Additionally, Tempus' biological modeling lab has supported around 65 research initiatives, enhancing understanding in therapy selection and drug discovery. These efforts align with Tempus' commitment to delivering data-driven insights that improve patient outcomes and accelerate scientific discovery.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempus AI Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250528572864) on May 28, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2538476829"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2538476829\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2538476829?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-28 20:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2538476829","market":"nz","top_or_hot":-1,"title":"Tempus AI Inc. Celebrates a Decade of Discovery with 1,500 Research Projects Advancing Precision Medicine","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/TEM\">Tempus AI</a> Inc. Celebrates a Decade of Discovery with 1,500 Research Projects Advancing Precision Medicine\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Tempus AI Inc. has announced its involvement in nearly 1,500 research projects over the past decade, marking a significant milestone in its mission to advance precision medicine and improve patient care. Utilizing its AI-powered platform, Tempus has collaborated with top academic institutions, community health systems, and biopharma organizations to propel cutting-edge research. Notably, Tempus has contributed to approximately 1,000 biopharma research projects and nearly 500 provider-led initiatives. Their diagnostic assays have yielded clinically-relevant insights across more than 200 projects. Additionally, Tempus' biological modeling lab has supported around 65 research initiatives, enhancing understanding in therapy selection and drug discovery. These efforts align with Tempus' commitment to delivering data-driven insights that improve patient outcomes and accelerate scientific discovery.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempus AI Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250528572864) on May 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tempus AI Inc. Celebrates a Decade of Discovery with 1,500 Research Projects Advancing Precision Medicine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTempus AI Inc. Celebrates a Decade of Discovery with 1,500 Research Projects Advancing Precision Medicine\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-28 20:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/TEM\">Tempus AI</a> Inc. Celebrates a Decade of Discovery with 1,500 Research Projects Advancing Precision Medicine\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Tempus AI Inc. has announced its involvement in nearly 1,500 research projects over the past decade, marking a significant milestone in its mission to advance precision medicine and improve patient care. Utilizing its AI-powered platform, Tempus has collaborated with top academic institutions, community health systems, and biopharma organizations to propel cutting-edge research. Notably, Tempus has contributed to approximately 1,000 biopharma research projects and nearly 500 provider-led initiatives. Their diagnostic assays have yielded clinically-relevant insights across more than 200 projects. Additionally, Tempus' biological modeling lab has supported around 65 research initiatives, enhancing understanding in therapy selection and drug discovery. These efforts align with Tempus' commitment to delivering data-driven insights that improve patient outcomes and accelerate scientific discovery.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempus AI Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250528572864) on May 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1861558580.USD","symbol_name":"日兴方舟颠覆性创新基金B","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nNDLc6RlyN:1","article_id":"2538476829","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2538476829","pubTimestamp":1748435427,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Tempus AI Inc. has announced its involvement in nearly 1,500 research projects over the past decade, marking a significant milestone in its mission to advance precision medicine and improve patient care. Utilizing its AI-powered platform, Tempus has collaborated with top academic institutions, community health systems, and biopharma organizations to propel cutting-edge research. Notably, Tempus has contributed to approximately 1,000 biopharma research projects and nearly 500 provider-led initiatives. Their diagnostic assays have yielded clinically-relevant insights across more than 200 projects. Additionally, Tempus' biological modeling lab has supported around 65 research initiatives, enhancing understanding in therapy selection and drug discovery. These efforts align with Tempus' commitment to delivering data-driven insights that improve patient outcomes and accelerate scientific discovery.Disclaimer: This news brief was created by Public Technologies  using generative artificial int","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1861558580.USD":"日兴方舟颠覆性创新基金B","BK4613":"AI应用软件","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","BK4611":"AI医疗","BK4121":"生命科学工具和服务","TEM":"Tempus AI"},"translate_title":"Tempus AI Inc.庆祝发现十周年，开展1,500个研究项目推进精准医疗","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEM":0.9},"content_text":"Tempus AI Inc. Celebrates a Decade of Discovery with 1,500 Research Projects Advancing Precision Medicine\n    \n\n        Tempus AI Inc. has announced its involvement in nearly 1,500 research projects over the past decade, marking a significant milestone in its mission to advance precision medicine and improve patient care. Utilizing its AI-powered platform, Tempus has collaborated with top academic institutions, community health systems, and biopharma organizations to propel cutting-edge research. Notably, Tempus has contributed to approximately 1,000 biopharma research projects and nearly 500 provider-led initiatives. Their diagnostic assays have yielded clinically-relevant insights across more than 200 projects. Additionally, Tempus' biological modeling lab has supported around 65 research initiatives, enhancing understanding in therapy selection and drug discovery. These efforts align with Tempus' commitment to delivering data-driven insights that improve patient outcomes and accelerate scientific discovery.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempus AI Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250528572864) on May 28, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}